AMO Pharma and Ranedis target rare genetic diseases in RND-001 deal

Privately-held companies AMO Pharma and Ranedis Pharmaceuticals have announced a collaboration to progress the development of RND-001 for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.

As part of the deal, financial terms of which were not disclosed, Ranedis has granted AMO an exclusive option to acquire the worldwide rights to RND-001 during the collaboration period.

"RND-001 reflects the qualities we look for in asset acquisition, such as strong scientific rationale and opportunity to address unmet needs in rare diseases"